Ro 11–1430, a New Retinoic Acid Derivative for the Topical Treatment of Acne

The clinical efficacy and tolerance of a new retinoic acid derivative, Ro 11–1430, in the treatment of acne vulgaris have been compared with those of tretinoin in a double-blind trial with 60 patients during 8 weeks. The efficacy of both drugs was good. Tretinoin showed a tendency to give better effect but this was not statistically significant. However, tolerance of the new derivative was better. 48 of the patients were treated with Ro 11–1430 for another 3 months with good effect and tolerance. In a long-term study, 32 patients with previous irritation of tretinoin have been treated with Ro 11–1430 between 1.5 and 17 months with good tolerance.